Does HLA-B27 Anterior Uveitis Come Back?
At a Glance
Testing positive for the HLA-B27 gene means your anterior uveitis (iritis) has a higher risk of returning, often suddenly and in alternating eyes. However, the long-term visual outlook is excellent if you work with your eye doctor to create a rapid-response plan for treating flares immediately.
In this answer
4 sections
Testing positive for the HLA-B27 gene does mean you have a statistically higher risk of your iritis (anterior uveitis) returning compared to someone who tests negative [1][2]. While this news can be frustrating, understanding this genetic link provides you and your care team with valuable information to better predict, manage, and quickly treat future flares.
How HLA-B27 Affects Your Iritis
HLA-B27-associated acute anterior uveitis is a specific type of inflammation that follows a distinct pattern. If your iritis is linked to this gene, you are more likely to experience:
- Sudden, intense onset: Flares typically come on very quickly. Often, a deep, aching pain or a sudden sensitivity to light (photophobia) are the very first warning signs, sometimes appearing before the eye even turns red [3][2].
- Alternating eyes: While a flare usually affects only one eye at a time, it is very common for future recurrences to bounce back and forth between your left and right eye [2].
- More frequent recurrences: People with the HLA-B27 gene tend to experience a higher number of flares over their lifetime than those without the gene [1].
- Younger age of onset: Symptoms often begin at a younger age compared to non-HLA-B27 anterior uveitis [1][4].
The Good News: Long-Term Outlook
Despite the higher likelihood of the inflammation returning, the long-term visual prognosis for HLA-B27 positive anterior uveitis is generally excellent [5][6][2]. Research shows that with prompt and appropriate treatment, rates of permanent vision loss are very low [5][6]. Studies have also found no major differences in final visual acuity between people who are HLA-B27 positive and those who are negative [7][8]. The key to protecting your vision is acting quickly when a flare starts [3][9].
The Importance of a Flare Action Plan
Because HLA-B27 positive flares come on so suddenly and can be severe, it is critical to have a rapid-response plan established with your ophthalmologist. A flare action plan ensures that you get treatment immediately, rather than waiting days for an appointment.
You should discuss:
- How to reach them quickly: Ask for the best way to contact the clinic (or an on-call doctor) after hours or on weekends.
- Stockpiling medication: Some doctors may prescribe a “standby” bottle of steroid eye drops to keep at home so you can start treatment at the very first sign of a flare. However, this must be strictly coordinated with your doctor to ensure safety [10][11]. Unsupervised use of steroid drops is dangerous because it can cause severe spikes in eye pressure (glaucoma), lead to early cataracts, or worsen an eye infection if you misdiagnose your symptoms [12][13][14].
- When to be seen: Clarify how soon you need to be examined in the clinic after starting your rapid-response plan.
The Systemic Connection
The HLA-B27 gene is strongly linked to a family of inflammatory conditions called spondyloarthropathies. These are conditions that affect the joints and sometimes other organs. The most common is ankylosing spondylitis (which causes lower back pain and stiffness), but others can affect your gut (like Crohn’s disease) or skin (like psoriasis) [15][16].
Because of this connection, your ophthalmologist may recommend that you see a rheumatologist for a full evaluation [17][18]. A rheumatologist visit might involve imaging, like an X-ray or MRI of your lower back, to check for joint inflammation. However, it is important to know that testing positive for the gene does not guarantee you will develop a systemic disease—many people with HLA-B27 only ever experience eye inflammation.
If you do experience very frequent iritis recurrences, repeated courses of steroid eye drops can eventually lead to complications like cataracts or high eye pressure [12][13]. In these cases, a rheumatologist can also discuss systemic medications, such as DMARDs (disease-modifying antirheumatic drugs) or biologics (targeted therapies that help calm the immune system) [19][20]. These are standard, effective options that have been proven to reduce the rate of iritis relapses while protecting your eye from chronic steroid exposure.
Common questions in this guide
Does testing positive for HLA-B27 mean my iritis will come back?
Will HLA-B27 anterior uveitis cause permanent vision loss?
What is a flare action plan for uveitis?
Why do I need to see a rheumatologist for eye inflammation?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my HLA-B27 positive status, can we establish a rapid-response flare action plan so I can begin treatment as soon as symptoms start?
- 2.Should I keep a 'standby' bottle of steroid eye drops at home, and what are your specific instructions for safely using them if I suspect a recurrence?
- 3.At what point in my recurrence frequency should we consider adding a systemic medication to prevent future flares and reduce my need for steroid drops?
- 4.Do you recommend that I see a rheumatologist to be screened for other HLA-B27 related conditions?
- 5.If my symptoms alternate to my other eye, should I treat it the same way or do I need a separate evaluation?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (20)
- 1
Clinical Characteristics of HLA-B27-Associated Anterior Uveitis in a Finnish Population-Based Cohort.
Leino A, Pesälä R, Siiskonen M, et al.
Ocular immunology and inflammation 2025; (33(1)):98-104 doi:10.1080/09273948.2024.2360593.
PMID: 38842206 - 2
Uveitis in Spondyloarthritis: An Overview.
Cantini F, Nannini C, Cassarà E, et al.
The Journal of rheumatology. Supplement 2015; (93()):27-9 doi:10.3899/jrheum.150630.
PMID: 26523051 - 3
Etiological and Clinical Characteristics of HLA-B27-associated Uveitis in a Tertiary Referral Center
İnanç M, Şimşek M, Çakar Özdal MP
Turkish journal of ophthalmology 2019; (49(1)):10-14 doi:10.4274/tjo.galenos.2018.53896.
PMID: 30829019 - 4
Comparison of Clinical Features in HLA-B27 Positive and Negative Patients With Axial Spondyloarthritis: Results From a Cohort of 4,131 Patients.
Zhang S, Wang Y, Peng L, et al.
Frontiers in medicine 2020; (7()):609562 doi:10.3389/fmed.2020.609562.
PMID: 33425955 - 5
Potential Predictors of Poor Visual Outcome in Human Leukocyte Antigen-B27-Associated Uveitis.
Verhagen FH, Brouwer AH, Kuiper JJ, et al.
American journal of ophthalmology 2016; (165()):179-87.
PMID: 26940162 - 6
Clinical Spectrum of HLA-B27-associated Ocular Inflammation.
Pathanapitoon K, Dodds EM, Cunningham ET, Rothova A
Ocular immunology and inflammation 2017; (25(4)):569-576 doi:10.1080/09273948.2016.1185527.
PMID: 27428361 - 7
Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis.
D'Ambrosio EM, La Cava M, Tortorella P, et al.
Seminars in ophthalmology 2017; (32(6)):689-701 doi:10.3109/08820538.2016.1170158.
PMID: 27404944 - 8
Clinical characteristics, treatment and ocular complications of HLA-B27-related anterior uveitis and HLA-B27-non related anterior uveitis.
Valls Pascual E, Fontanilla Ortega P, Vicens Bernabeu E, et al.
Reumatologia clinica 2016; (12(5)):244-7.
PMID: 26708737 - 9
Ocular manifestations of HLA B 27 associated uveitis: a study of 255 cases from a tertiary eye care centre from South India.
Lakra R, Elango N, George AE, et al.
International ophthalmology 2021; (41(11)):3743-3748 doi:10.1007/s10792-021-01943-6.
PMID: 34313928 - 10
[Differential diagnosis of anterior uveitis].
Thurau S, Pleyer U
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2016; (113(10)):879-892 doi:10.1007/s00347-016-0328-3.
PMID: 27578315 - 11
Diagnosis, Treatment, and Prevention of Noninfectious Acute Anterior Uveitis with or without Human Leukocyte Antigen B27 in Adults - Expert Consensus in Taiwan.
Chao YJ, Hung JH, Lin CP, et al.
Ocular immunology and inflammation 2024; (32(2)):226-233 doi:10.1080/09273948.2023.2165113.
PMID: 36701640 - 12
Impact of complications in adult anterior uveitis in a Finnish single-centre registry study.
Leino A, Siiskonen M, Ohtonen P, Hautala NM
BMJ open ophthalmology 2025; (10(1)) doi:10.1136/bmjophth-2025-002210.
PMID: 41327639 - 13
Topical Ganciclovir in Cytomegalovirus Anterior Uveitis.
Antoun J, Willermain F, Makhoul D, et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2017; (33(4)):313-318 doi:10.1089/jop.2016.0138.
PMID: 28426277 - 14
Multiple Anterior Chamber Paracenteses May Be Needed to Identify Cytomegalovirus Anterior Uveitis.
Benador-Shen C, Shantha J, Lee J, et al.
American journal of ophthalmology 2025; (269()):189-194 doi:10.1016/j.ajo.2024.08.025.
PMID: 39218387 - 15
Ocular features of the HLA-B27-positive seronegative spondyloarthropathies.
Jhaj G, Kopplin LJ
Current opinion in ophthalmology 2018; (29(6)):552-557 doi:10.1097/ICU.0000000000000525.
PMID: 30148724 - 16
HLA-B27-positive anterior uveitis : Clinical aspects, diagnostics, interdisciplinary management, and treatment.
Werkl P, Rademacher J, Pleyer U
Die Ophthalmologie 2024; (121(Suppl 1)):12-22 doi:10.1007/s00347-023-01960-z.
PMID: 38085287 - 17
Clinical spectrum of HLA-B27-associated ocular inflammation.
Pyare R, Majumder PD
Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2022; (14(28)):116-134 doi:10.3126/nepjoph.v14i2.50679.
PMID: 37609973 - 18
An Overview of Pediatric Uveitis.
Tuğal-Tutkun İ
Turkish archives of pediatrics 2023; (58(4)):363-370 doi:10.5152/TurkArchPediatr.2023.23086.
PMID: 37357450 - 19
The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study.
Zu Hoerste MM, Walscheid K, Tappeiner C, et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2018; (256(10)):1985-1992 doi:10.1007/s00417-018-4082-x.
PMID: 30069748 - 20
Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis.
Yazgan S, Celik U, Işık M, et al.
International ophthalmology 2017; (37(1)):139-145 doi:10.1007/s10792-016-0239-y.
PMID: 27154720
This page provides general educational information about HLA-B27 positive anterior uveitis recurrences. Always consult your ophthalmologist or rheumatologist for a personalized flare action plan and medical treatment.
Get notified when new evidence is published on Anterior uveitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.